Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/fabry mice

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1454-1461

  Pacienza, Natalia ^a   Yoshimitsu, Makoto ^a,b   Mizue, Nobuo ^a   Au, Bryan C Y ^a   Wang, James C M ^a   Fan, Xin ^a   Takenaka, Toshihiro ^b   Medin, Jeffrey A ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ENHANCED GREEN FLUORESCENT PROTEIN; GLOBOTRIAOSYLCERAMIDE; INTERLEUKIN 2 RECEPTOR ALPHA; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW CELL; CD34+ CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELLS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; LIVER; MALE; MOUSE; NONHUMAN; SPLEEN; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

MURINAE; MUS;

EID: 84863430009     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.64     Document Type: Conference Paper

References (28)

1. Brady, RO, Gal, AE, Bradley, RM, Martensson, E, Warshaw, AL and Laster, L (1967). Enzymatic defect in Fabry disease: ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167.
2. MacDermot, KD, Holmes, A and Miners, AH (2001). Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750-760. (Pubitemid 33032930)
3. MacDermot, KD, Holmes, A and Miners, AH (2001). Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775. (Pubitemid 33032933)
4. Schiffmann, R (2006). Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg 106: 61-65. (Pubitemid 44044035)
5. Lidove, O, Joly, D, Barbey, F, Bekri, S, Alexandra, JF, Peigne, V et al. (2007). Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 61: 293-302.
6. Rohrbach, M and Clarke, JT (2007). Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67: 2697-2716. (Pubitemid 350224380)
7. Moore, DF, Ries, M, Forget, EL and Schiffmann, R (2007). Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. Pharmacoeconomics 25: 201-208. (Pubitemid 46376830)
8. Breunig, F, Weidemann, F, Strotmann, J, Knoll, A and Wanner, C (2006). Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69: 1216-1221.
9. Schiffmann, R, Askari, H, Timmons, M, Robinson, C, Benko, W, Brady, RO et al. (2007). Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583. (Pubitemid 46717525)
10. Thofehrn, S, Netto, C, Cecchin, C, Burin, M, Matte, U, Brustolin, S et al. (2009). Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience. Ren Fail 31: 773-778.
11. Caballero, L, Climent, V, Hernández-Romero, D, Quintanilla, MA, de la Morena, G and Marín, F (2010). Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations. Curr Med Chem 17: 1679-1689.
12. Medin, JA, Tudor, M, Simovitch, R, Quirk, JM, Jacobson, S, Murray, GJ et al. (1996). Correction in trans for Fabry disease: expression, secretion and uptake of alphagalactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 93: 7917-7922.
13. Takenaka, T, Hendrickson, CS, Tworek, DM, Tudor, M, Schiffmann, R, Brady, RO et al. (1999). Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol 27: 1149-1159. (Pubitemid 29284322)
14. Takenaka, T, Murray, GJ, Qin, G, Quirk, JM, Ohshima, T, Qasba, P et al. (2000). Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA 97: 7515-7520. (Pubitemid 30431495)
15. Qin, G, Takenaka, T, Telsch, K, Kelley, L, Howard, T, Levade, T et al. (2001). Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 98: 3428-3433. (Pubitemid 32220862)
16. Yoshimitsu, M, Sato, T, Tao, K, Walia, JS, Rasaiah, VI, Sleep, GT et al. (2004). Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101: 16909-16914. (Pubitemid 39601337)
17. Ohshima, T, Murray, GJ, Swaim, WD, Longenecker, G, Quirk, JM, Cardarelli, CO et al. (1997). α-Galactosidase A deficient mice: A model of Fabry disease. Proc Natl Acad Sci USA 94: 2540-2544. (Pubitemid 27136911)
18. Ramsubir, S, Nonaka, T, Girbés, CB, Carpentier, S, Levade, T and Medin, JA (2008). In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab 95: 133-141.
19. Ohshima, T, Schiffmann, R, Murray, GJ, Kopp, J, Quirk, JM, Stahl, S et al. (1999). Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 96: 6423-6427. (Pubitemid 29256681)
20. Schiffmann, R, Askari, H, Timmons, M, Robinson, C, Benko, W, Brady, RO et al. (2007). Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583. (Pubitemid 46717525)
21. Schiffmann, R (2009). Fabry disease. Pharmacol Ther 122: 65-77.
22. Beck, M (2010). Fabry Disease. Springer: Dordrecht, Heidelberg, London, New York. ch. 24, pp. 381-388.
23. Yoshimitsu, M, Higuchi, K, Ramsubir, S, Nonaka, T, Rasaiah, VI, Siatskas, C et al. (2007). Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 14: 256-265. (Pubitemid 46152629)
24. Noort, WA, Willemze, R and Falkenburg, JH (1998). Comparison of repopulating ability of hematopoietic progenitor cells isolated from human umbilical cord blood or bone marrow cells in NOD/SCID mice. Bone Marrow Transplant 22 (suppl. 1): S58-S60. (Pubitemid 28375283)
25. Hofling, AA, Vogler, C, Creer, MH and Sands, MS (2003). Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood 101: 2054-2063. (Pubitemid 36237614)
26. Wulf-Goldenberg, A, Eckert, K and Fichtner, I (2008). Cytokine-pretreatment of CD34(+) cord blood stem cells in vitro reduces long-term cell engraftment in NOD/SCID mice. Eur J Cell Biol 87: 69-80.
27. Mizuguchi, H, Xu, Z, Ishii-Watabe, A, Uchida, E and Hayakaw, T (2000). IRESdependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376-382.
28. McKenzie, JL, Gan, OI, Doedens, M and Dick, JE (2005). Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood 106: 1259-1261. (Pubitemid 41129588)